International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Osteoarthritis Management Reimagined: Bridging Traditional Therapies with Nanotechnology and Personalized Medicine for Better Outcomes

Swati Jirankali[1], Bhaskar Kurangi[2], Rajgouda Patil[3], Gururaj Kanabargi[4]

[1, 3, 4]M Pharm, [4]Associate Professor

[1, 2, 3, 4]Department of Pharmaceutics, KLE College of Pharmacy Belagavi, KLE Academy of Higher Education and Research, Belagavi, 590010, Karnataka, India

Abstract

Osteoarthritis (OA) is a leading cause of pain and disability worldwide, profoundly affecting patients' mobility and quality of life. Traditional management strategies—such as nonsteroidal anti-inflammatory drugs, corticosteroid injections, and surgical interventions—primarily target symptom relief but often fall short in modifying disease progression and can be associated with significant side effects. Recent breakthroughs in nanotechnology have opened new avenues for OA treatment, with nanoformulations offering targeted drug delivery, prolonged therapeutic action, and minimized systemic toxicity. Innovations like liposomes, polymeric nanoparticles, and 3D-printed nanomaterial scaffolds are enabling more precise and sustained interventions, while theranostic platforms are beginning to integrate real-time diagnostics with therapy for truly personalized care. Despite these exciting developments, challenges such as manufacturing complexity, cost, and regulatory hurdles must be addressed before these technologies can be widely adopted in clinical practice. Ongoing research and well-designed clinical trials are crucial for validating the safety and efficacy of these novel approaches. Ultimately, the integration of nanotechnology and personalized medicine holds great promise for revolutionizing osteoarthritis management, offering hope for improved outcomes and a better quality of life for patients.

Keywords: Osteoarthritis, Nanotechnology, Nanoformulations, Personalized Medicine, Theranostics

1. Introduction

Epidemiology:

Osteoarthritis (OA) is a chronic, degenerative joint disease marked by the progressive loss of articular cartilage, accompanied by pain, stiffness, and swelling in the affected joints. OA is the most common form of arthritis and a leading cause of disability among older adults. The disease primarily affects weight-bearing joints such as the knees, hips, and spine, but it can also involve the hands and other joints [1].

Globally, OA affects hundreds of millions of people, with its prevalence rising with age. Women and individuals with risk factors such as obesity, joint injury, or repetitive stress are particularly susceptible. OA can significantly reduce quality of life by limiting mobility and independence, leading to challenges in daily activities, loss of productivity, and increased healthcare costs. Its socioeconomic impact is substantial, as it is a major cause of work disability and a driver of healthcare utilization in aging populations [1,2]

Pathophysiology:

The pathophysiology of OA involves the entire joint structure. The hallmark feature is the gradual degradation of articular cartilage, which normally acts as a cushion between bones. This breakdown is driven by an imbalance between the synthesis and degradation of cartilage matrix, often triggered by mechanical stress and inflammatory mediators [1,3]

As cartilage erodes, the underlying subchondral bone responds by becoming denser (sclerosis) and forming osteophytes (bone spurs), which further alter joint mechanics. The synovial membrane, which lines the joint, can also become inflamed, contributing to pain and swelling. These changes collectively lead to joint space narrowing, reduced range of motion, and chronic pain. In advanced cases, bone cysts and pronounced joint deformities may develop. OA is thus recognized as a multifactorial disease involving cartilage loss, synovial inflammation, and subchondral bone remodeling [1,3,4]

Osteoarthritis is a complex joint disorder characterized primarily by the progressive degradation of articular cartilage and remodeling of subchondral bone, driven by an interplay of mechanical, biochemical, and inflammatory factors. The disease process begins with mechanical stress and injury to the cartilage, which activates chondrocytes—the cells responsible for maintaining cartilage integrity. These cells respond abnormally by producing increased levels of degradative enzymes such as matrix metalloproteinases (MMPs) and aggrecanases, which break down collagen and proteoglycans, the essential components of the cartilage extracellular matrix (ECM). This degradation leads to loss of cartilage resilience and joint space narrowing. Concurrently, subchondral bone undergoes sclerosis and reactive remodeling, including osteophyte formation, which further alters joint biomechanics and contributes to pain and dysfunction [5,6].

Inflammation plays a crucial role in OA pathogenesis, although it is typically low-grade compared to other arthritides. Proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α) are upregulated in the joint environment, stimulating the expression of enzymes like inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). These enzymes generate inflammatory mediators nitric oxide (NO) and prostaglandin E2 (PGE2), which contribute to cartilage breakdown by promoting chondrocyte apoptosis, inhibiting matrix synthesis, and enhancing the production of MMPs [7]. Additionally, activation of the proteinase-activated receptor 2 (PAR-2) pathway amplifies inflammatory signaling and matrix degradation. The cumulative effect of these molecular and cellular events disrupts the balance between catabolic and anabolic processes in the joint, leading to progressive cartilage loss, synovitis, pain, and impaired joint function [8,9].

2. Traditional Approaches to Osteoarthritis Management

2.1 Medications and Their Limitations (Pharmacological approaches)



Figure 1: Medications for osteoarthritis management

1. Oral Medications

Oral medicines are commonly used to relieve osteoarthritis pain. While they don't stop the disease from progressing, they can help reduce pain and improve movement, making daily activities easier.

i. Acetaminophen (Paracetamol): Often the first option for mild to moderate OA pain. It helps ease discomfort but doesn't reduce inflammation.

ii. Nonsteroidal Anti-inflammatory Drugs (NSAIDs):
   - Non-selective NSAIDs like ibuprofen and naproxen help relieve both pain and inflammation. These are widely available over the counter and in stronger prescription doses.
   - COX-2 Selective Inhibitors such as celecoxib are designed to reduce inflammation with a lower risk of stomach irritation compared to regular NSAIDs.

iii. Duloxetine: Originally developed to treat depression, this medication is also approved for managing chronic pain, including pain from OA. It works by altering pain signals in the brain.

iv. Tramadol: This is a prescription-only pain reliever for more severe OA pain that isn't controlled with other medications. It belongs to the opioid family, so it's used with caution due to the risk of dependence.

2. Topical Medications

Topical treatments are applied directly to the skin over sore joints. They're great for targeting pain locally, especially in joints like the knees or fingers, and generally have fewer side effects than oral medications.

i. Topical NSAIDs (e.g., diclofenac gel): These provide anti-inflammatory relief directly where it hurts, without affecting the whole body.
ii. Capsaicin Cream: Made from chili peppers, this cream helps block pain signals by reducing a pain-transmitting substance in nerves.
iii. Salicylate-based Creams: Contain aspirin-like ingredients that can help relieve pain in the area where they're applied.
iv. Counterirritants (menthol, camphor): These create a warming or cooling feeling that distracts the brain from the pain.

3. Injection-Based Therapies

When pills and creams aren't enough, injections can offer more direct relief by targeting the affected joint.

i. Corticosteroid Injections: These deliver a strong anti-inflammatory medicine straight into the joint, offering quick and often significant pain relief.
ii. Hyaluronic Acid Injections: This treatment mimics natural joint fluid and helps cushion and lubricate the joint, especially useful in the knees.

4. Supplements and Alternative Therapies

Some people explore supplements and natural options alongside medical treatments. While results vary from person to person, a few are commonly used.

Glucosamine and Chondroitin: These are natural substances found in cartilage. Some people take them to support joint health, though research on their effectiveness is mixed. Figure 1. depicts various medications for managing osteoarthritis [10,11].

2.2 Non-Drug Interventions (Non-Pharmacological Approaches)

- Physical Therapy and Exercise: Physical therapy plays a vital role in managing osteoarthritis by improving joint mobility and strengthening the muscles around affected joints. Tailored exercise programs, including strengthening, stretching, aerobic, and balance exercises, help reduce pain, enhance muscle support, and maintain or increase the range of motion. Regular low-impact activities like walking, cycling, swimming, and tai chi not only improve joint function but also promote overall cardiovascular health. Consistency and gradual progression are key to avoiding overexertion and maximizing benefits. Physical therapy may also include manual techniques and modalities such as ultrasound or heat therapy to alleviate stiffness and pain. Overall, exercise therapy is strongly supported by clinical evidence as a first-line treatment for osteoarthritis, helping delay disease progression and improve quality of life [12].
- Weight Management: Maintaining a healthy weight is crucial in osteoarthritis management because excess body weight increases mechanical stress on weight-bearing joints, accelerating cartilage wear and joint damage. Weight reduction has been shown to significantly decrease joint pain and improve function, especially in the knees and hips. Even modest weight loss can reduce the load on joints, lessen inflammation, and improve mobility, making it easier to engage in physical activity and further support joint health. Combining weight management with exercise amplifies the benefits and helps break the cycle of pain and inactivity common in osteoarthritis patients [13].

- Assistive Devices: Assistive devices such as braces, orthotics, and walking aids provide additional joint support and stability, helping to reduce pain and improve function. Knee braces can offload stress from damaged areas of the joint, while orthotic shoe inserts help correct alignment and distribute weight more evenly during movement. These devices can enhance mobility, reduce the risk of falls, and increase confidence in daily activities. They are often used alongside physical therapy and lifestyle modifications to optimize joint protection and symptom relief [14].

2.3 Surgical Therapy in Osteoarthritis: Indications and Challenges

- Arthroscopy, a minimally invasive surgical procedure, has limited benefit for osteoarthritis (OA). Current evidence and guidelines indicate that arthroscopy does not provide significant or lasting pain relief or functional improvement for most OA patients. Any pain relief tends to be short-lived, and the procedure is generally not recommended except in specific situations such as a truly locked knee or the presence of loose bodies causing mechanical symptoms. Complications, though rare, can include infection and blood clots, and recovery may take several weeks. Consequently, arthroscopy is seldom considered for OA unless conservative treatments have failed and there is a clear mechanical issue [15].
- Osteotomy and joint replacement (arthroplasty) are more invasive surgical options, typically reserved for end-stage OA [16] :
  - Osteotomy involves cutting and realigning bones to redistribute weight across the joint. It is mainly considered for younger, active patients with malalignment and localized OA, aiming to delay joint replacement. However, it carries risks such as malalignment, fractures, vascular injury, and may complicate future joint replacement surgeries. Careful patient selection is critical to minimize complications and maximize functional outcomes.
  - Joint Replacement (total hip or knee arthroplasty) is the definitive surgical option for severe, end-stage OA. It reliably provides substantial pain relief, restores function, and improves quality of life. However, it is invasive, expensive, and associated with a long recovery period. Risks include infection, blood clots, prosthesis wear, and the need for revision surgery, especially in younger or more active patients.

When Is Surgery Considered?

Surgery for OA is considered only after conservative measures (such as physical therapy, medications, injections, and lifestyle modifications) have failed to provide adequate relief and the patient's quality of life is significantly impaired. Typical indications include:

- Severe, persistent pain that dominates daily life and is unresponsive to non-surgical treatments
- Marked restriction in mobility, impacting basic activities such as walking or dressing
- Joint instability or deformity that threatens safety and independence
- Advanced joint damage confirmed by imaging and clinical assessment

The decision to proceed with surgery must be individualized, taking into account factors such as age, activity level, comorbidities, anatomical considerations, and patient preferences. Surgery should always be the last resort, used only when all other options have failed and the potential benefits outweigh the risks.

Challenges Involved in Surgical Therapy [17]:

- Patient Selection: Choosing appropriate candidates for surgery is crucial. Poor selection can lead to suboptimal outcomes, complications, or the need for additional procedures.
- Surgical Risks: All surgeries carry risks such as infection, blood clots, neurovascular injury, and complications related to anesthesia or implants.
- Recovery and Rehabilitation: Both osteotomy and joint replacement require significant postoperative rehabilitation, with varying recovery times and demands on the patient.
- Cost and Resource Use: Joint replacement is expensive and may not be accessible to all patients. Revision surgeries for failed implants add further complexity and cost.
- Long-Term Outcomes: While joint replacement is highly successful, prostheses have a finite lifespan, and younger patients may require revision surgery later.

"Surgery should always be the last option – it should only be considered if conservative measures are no longer sufficiently effective and the quality of life is significantly impaired.

2.4 Limitations of Conventional Therapies

Limitations of Conventional Therapies for Osteoarthritis

Conventional therapies for osteoarthritis (OA) are primarily focused on alleviating symptoms such as pain and stiffness, rather than addressing the underlying disease process. While these treatments can improve daily comfort and function, they come with several notable limitations [18].

- Symptomatic Relief Only
  Most standard OA treatments—including NSAIDs, acetaminophen, and intra-articular injections—are designed to manage symptoms, not to halt or reverse the progression of joint degeneration. As a result, while patients may experience temporary relief, the disease continues to advance over time, potentially leading to worsening pain and disability.
- Frequent Dosing and Systemic Side Effects
  Many conventional medications require frequent dosing to maintain their effect. Oral analgesics and anti-inflammatories, for example, must often be taken daily. This increases the risk of systemic side effects, such as gastrointestinal irritation, cardiovascular complications, kidney dysfunction, and, in the case of opioids, drowsiness, dependency, and even increased mortality in some populations. Even intra-articular corticosteroid injections, while targeted, can have systemic effects if used repeatedly and are not recommended for long-term management due to diminishing efficacy and potential joint damage.
- Poor Targeting to Affected Tissues
  Conventional systemic therapies often lack specificity, meaning they affect the entire body rather than just the diseased joint. This poor targeting can limit the effectiveness of treatment at the site of pathology and increase the likelihood of adverse effects elsewhere in the body. Even with intra-articular therapies, the relief is often short-lived, and not all patients respond equally well.
  Recent research is increasingly focused on developing therapies that address these shortcomings—such as molecular targeted agents, biologics, and regenerative medicine approaches—but these are not yet standard care and require further validation before widespread adoption. "Current treatment for OA is limited to control of symptoms. At this time, there are no pharmacological agents capable of retarding the progression of OA or reversing joint damage [19].

3. Nanoformulations in Osteoarthritis (OA) Management

3.1 Overview of Nanotechnology in Medicine

Nanotechnology in medicine involves the use of nanoparticles—materials sized between 1 and 100 nanometers—to improve drug delivery and therapeutic outcomes. These nanoscale carriers can be engineered for targeted delivery to specific tissues, such as cartilage or synovium in OA, and offer controlled, sustained drug release. The main advantages include increased bioavailability of drugs, precise targeting to diseased tissues, and a reduction in systemic side effects compared to conventional therapies [20].

3.2 Types of Nanoformulations for OA: different nanoparticle approaches for osteoarthritis treatment are shown in Figure 2.



Figure 2: Nanoparticles for osteoarthritis treatment

- Liposomes: These are biocompatible vesicles capable of encapsulating drugs for sustained intra-articular release. For example, hyaluronic acid-liposome formulations loaded with diclofenac and dexamethasone (HA-Lipo-DIC/DEX) have shown prolonged pain relief and reduced inflammation in OA models [21].
- Polymeric Nanoparticles: Carriers made from PLGA, PEG, or chitosan provide controlled and prolonged drug release, improving the stability and retention of therapeutic agents in the joint.
- Solid Lipid Nanoparticles & Micelles: These systems enhance the solubility and stability of hydrophobic drugs, ensuring better absorption and longer-lasting effects [22].
- Hydrogels & Nanocomposites: Injectable hydrogels can serve both as lubricants and drug depots, releasing medication directly within the joint space while supporting cartilage repair.
- Dendrimers & Nanospheres: These highly branched structures allow for multivalent drug or gene loading, enabling combination therapies and gene delivery for OA.

3.3 Mechanisms and Strategies [23]

- Targeted Delivery: Nanoparticles can be surface-modified with antibodies or peptides to home in on cartilage or synovial tissue, maximizing local drug concentration while sparing healthy tissues.
- Stimuli-Responsive Release: Some nanoformulations are engineered to release their payload in response to local triggers such as pH changes, enzymes, or oxidative stress in inflamed joints, ensuring on-demand drug delivery.
- Combination Therapy: Nanocarriers can co-deliver multiple agents—such as anti-inflammatories, analgesics, and disease-modifying drugs—within a single formulation, addressing multiple OA pathways simultaneously.
- Gene Therapy: Nanoparticles are being developed to deliver genetic material (siRNA, miRNA, or DNA) for modulating gene expression involved in OA progression, offering a potential for disease modification [24].

3.4 Preclinical and Clinical Evidence

Recent studies highlight several benefits of nanoformulations in OA management [25,26]:

- Prolonged Drug Retention: Nanoparticles, such as HA-modified carriers, have demonstrated extended retention in the joint cavity, reducing the need for frequent dosing and enhancing therapeutic efficacy.
- Enhanced Cartilage Repair & Reduced Inflammation: Nanotechnology-based therapies have shown improved cartilage regeneration and significant reduction in joint inflammation in both in vitro and animal models.
- Lower Systemic Toxicity: By concentrating drug action within the joint and minimizing systemic exposure, nanoformulations reduce the risk of adverse effects commonly associated with conventional OA medications.

4. Comparing Nanoformulations and Conventional Treatments for Osteoarthritis

Differences between nanoformulations and conventional therapies is illustrated in Table 1.

- Effectiveness in Symptom Relief and Disease Modification
  Nanoformulations offer significant advantages over conventional OA treatments. While traditional therapies—like NSAIDs and corticosteroids—primarily provide short-term symptom relief without altering disease progression, nanoformulations are engineered for targeted, sustained delivery. This results in longer drug retention within the joint, more effective pain control, and the potential for cartilage repair and regeneration. Recent studies on nanofat and polymeric nanoparticles have shown not only improved pain relief and functional outcomes but also evidence of cartilage regeneration and reduced inflammation, suggesting true disease-modifying potential. In contrast, conventional therapies rarely impact the underlying joint pathology [27].
- Safety and Side Effect Profiles
  Conventional treatments are often associated with systemic side effects—such as gastrointestinal, cardiovascular, or renal complications—due to poor targeting and frequent dosing. Nanoformulations, by contrast, concentrate their action locally within the joint, minimizing systemic exposure and reducing the risk of adverse effects. Clinical studies on nanofat and

liposomal nanoparticles report mostly mild, transient local reactions (e.g., swelling, discomfort at the injection site) and a low incidence of serious complications. However, some nanomaterials may induce immune responses or cytotoxicity, and their long-term safety requires further investigation [28].

- Impact on Patient Adherence and Quality of Life
  Nanoformulations can improve patient adherence by reducing the frequency of administration—thanks to their prolonged retention and controlled release properties. This translates into fewer injections or doses, less disruption to daily life, and more consistent symptom control. Patients report better pain management, improved mobility, and enhanced quality of life following nano-based therapies compared to conventional regimens. The potential for actual cartilage repair further contributes to long-term functional gains.
- Barriers to Widespread Use [29]
  - Despite their promise, several barriers hinder the widespread adoption of nanoformulations in OA:
  - Manufacturing Complexity: Production of nanoparticles requires specialized equipment, strict quality controls, and standardized protocols, which can be challenging to scale up.
  - Cost: The advanced technology and rigorous testing involved make nanoformulations more expensive than traditional drugs, potentially limiting accessibility.
  - Regulatory Hurdles: Nanomedicines face complex regulatory pathways, as agencies require extensive safety and efficacy data, particularly for new materials and delivery systems. Long-term data on safety and effectiveness are still limited, delaying approval and clinical adoption.
  - Knowledge Gaps: Many aspects of nanoparticle metabolism, long-term effects, and optimal dosing are not yet fully understood, necessitating further research and large-scale clinical trials [30].

Table 1: Nanoformulations versus conventional osteoarthritis therapies

Feature	Nanoformulations	Conventional Therapies
Symptom Relief	Prolonged, targeted, potential for regeneration	Short-term, non-specific
Disease Modification	Possible (cartilage repair, anti-inflammatory)	Rare
Side Effects	Mostly local, mild, less systemic	Frequent systemic, sometimes severe
Dosing Frequency	Reduced (weeks to months)	Frequent (daily to weekly)
Patient Adherence/Quality	Improved	Variable
Barriers	Cost, manufacturing, regulatory, knowledge	Generally accessible, well-established

5. Looking Ahead: Future Directions in Osteoarthritis Treatment

5.1 Combining Therapy and Diagnostics (Theranostics)

Theranostics—integrating therapeutic and diagnostic capabilities into a single platform—is emerging as a transformative approach in osteoarthritis (OA) care. For example, injectable self-healing hyaluronic

acid hydrogels labeled with iodine allow both real-time imaging of drug delivery and sustained treatment within the joint. These smart materials enable clinicians to monitor the persistence and distribution of therapies in vivo, helping tailor interventions and predict treatment responses based on imaging data. Such theranostic platforms not only improve the precision of OA management but also provide valuable insights into disease progression and therapeutic efficacy [31,32,33], Table 2 represents key examples and applications for theranostic nanoparticles for osteoarthritis.

Table 2: Theranostic Nanoparticle Approaches for Osteoarthritis: Key Examples and Applications

Formulation Type / Name	Diagnostic Modality	Therapeutic Function	Status / Notes
SPIO (Superparamagnetic Iron Oxide) Nanoparticles	MRI	Drug delivery, cartilage targeting	Preclinical, peptide-modified for OA
Antibody-targeted fluorescent nanosomes	Fluorescence imaging	Drug/siRNA delivery	Preclinical, targeted to damaged cartilage
Molybdenum disulfide-gold nanorods	Photoacoustic & NIR imaging	NIR-guided photothermal analgesic therapy	Preclinical, NGF-targeted for OA pain
Quantum Dots, Carbon Nanotubes, Gold/Silica NPs	Various (MRI, CT, fluorescence)	Drug/gene delivery	Investigational, multi-platform use

5.2 Toward Personalized and Precision Medicine

Recent genetic studies have uncovered multiple new genes and biological pathways implicated in OA, paving the way for more individualized treatments. By integrating genetic, molecular, and imaging data, researchers are moving toward precision medicine—where therapies are tailored to each patient's unique disease profile. This approach holds promise for identifying patients most likely to benefit from specific drugs, repurposing existing medications for new OA indications, and accelerating the development of targeted biologics that can modify disease progression and restore joint health. Personalized strategies, such as using stem cell-derived exosomes or biomaterial-based scaffolds, are also being explored to address the diverse presentations of OA [34, 35,36], Table 3 summarizes the various personalized medicine strategies in osteoarthritis

Table 3: Personalized medicine strategies in osteoarthritis

Approach	Example/Description
Biomarker-guided Nanoformulations	Liposomes or nanoparticles loaded with anti-inflammatory drugs, tailored to patient biomarkers
Quantum Dot Nanoprobes	Quantum dots conjugated with peptides for early detection of cartilage-degrading enzymes (MMPs)
3D-Printed Nanomaterial Scaffolds	Custom scaffolds using nanomaterials for cartilage regeneration, matched to patient joint anatomy
Biosensor-Integrated Drug Delivery	Nanosensors for real-time monitoring of nitric oxide or ADAMTS activity in OA joints
Serum Biomarker Panels for Stratification	Proteomic panels from blood samples to predict OA progression and guide therapy

5.3 Next-Generation Drug Delivery Platforms

Innovative drug delivery systems—such as hydrogels, nanocomposites, and microspheres—are being developed to provide controlled, sustained, and targeted release of therapeutics. These platforms can encapsulate not only conventional drugs but also regenerative agents like mesenchymal stem cells (MSCs) or their exosomes, enhancing cartilage repair and reducing inflammation. For instance, gelatin microspheres loaded with MSCs have shown efficacy in both preclinical and early clinical studies, offering long-lasting joint protection and pain relief without damaging healthy tissue. The ability to fine-tune release profiles and combine multiple agents in a single delivery system represents a major advance over traditional treatments.

5.4 Bringing Innovations to the Clinic

Translating these scientific breakthroughs into real-world therapies requires overcoming several challenges, including large-scale manufacturing, regulatory approval, and ensuring safety and efficacy in diverse patient populations. Early-phase clinical trials of advanced biomaterials, stem cell therapies, and theranostic agents have shown encouraging results, with improvements in pain, function, and joint structure. Continued collaboration between researchers, clinicians, and industry partners is essential to refine these approaches, validate their benefits in larger studies, and make them accessible to patients worldwide. As these innovations progress, they offer hope for more effective, personalized, and disease-modifying OA treatments in the near future [37,38,39,40].

6. Conclusion

Osteoarthritis remains a significant clinical challenge, with conventional therapies often limited to providing only symptomatic relief and failing to address the underlying disease processes. These traditional approaches, while helpful in managing pain and improving mobility, are frequently associated with systemic side effects, require frequent dosing, and lack the ability to target affected joint tissues precisely. As a result, many patients continue to experience progressive joint degeneration and diminished quality of life despite ongoing treatment.

The emergence of nanotechnology in medicine offers a promising new direction for osteoarthritis management. Nanoformulations—such as liposomes, polymeric nanoparticles, hydrogels, and dendrimers—are designed to deliver drugs directly to the site of joint damage, prolong therapeutic effects, and minimize unwanted systemic exposure. These advanced delivery systems can be engineered for targeted, controlled, and even stimuli-responsive release, potentially transforming how we approach both symptom control and disease modification in OA. Early preclinical and clinical studies have demonstrated encouraging results, including improved drug retention in joints, enhanced cartilage repair, and reduced inflammation, all with a lower risk of systemic toxicity.

Despite these advances, it is important to recognize that nanomedicine for osteoarthritis is still in its early stages. There is a pressing need for further research to optimize nanoformulation design, understand their long-term safety, and establish standardized manufacturing processes. Large-scale, well-controlled clinical trials are essential to confirm the efficacy and safety of these novel therapies in diverse patient populations. Additionally, regulatory pathways must evolve to keep pace with the rapid innovation in this field, ensuring that new treatments are both effective and accessible.

Looking ahead, the integration of theranostics, personalized medicine, and next-generation drug delivery platforms holds the potential to revolutionize osteoarthritis care. By combining advanced diagnostics

with tailored therapies, clinicians may soon be able to monitor disease progression in real time and deliver individualized treatments that address each patient's unique needs. As these technologies advance from the laboratory to the clinic, they offer genuine hope for not only improving symptoms but also altering the course of osteoarthritis and restoring joint health.

In summary, nanotechnology represents a transformative step forward in osteoarthritis management. With continued research, collaboration, and innovation, these cutting-edge approaches may soon offer patients safer, more effective, and more personalized options for living well with osteoarthritis.

7. References

[1] Allen KD, Thoma LM, Golightly YM. (2022). Epidemiology of osteoarthritis. Osteoarthritis and cartilage, 30(2), 184-95.

[2] Minnig MC, Golightly YM, Nelson AE. (2024). Epidemiology of osteoarthritis: literature update 2022–2023. Current Opinion in Rheumatology, 36(2), 108-12.

[3] Loeser RF, Goldring SR, Scanzello CR, Goldring MB. (2012). Osteoarthritis: a disease of the joint as an organ. Arthritis and rheumatism, 64(6), 1697.

[4] Courties A, Kouki I, Soliman N, Mathieu S, Sellam J. (2024). Osteoarthritis year in review 2024: Epidemiology and therapy. Osteoarthritis and Cartilage, 32(11), 1397-404.

[5] Molnar V, Pavelić E, Vrdoljak K, Čemerin M, Klarić E, Matišić V, Bjelica R, Brlek P, Kovačić I, Tremolada C, Primorac D. (2022). Mesenchymal stem cell mechanisms of action and clinical effects in osteoarthritis: a narrative review. Genes, 13(6), 949.

[6] Sukhikh S, Noskova S, Ivanova S, Ulrikh E, Izgaryshev A, Babich O. (2021). Chondroprotection and molecular mechanism of action of phytonutraceuticals on osteoarthritis. Molecules, 26(8), 2391.

[7] Barry F. MSC therapy for osteoarthritis: an unfinished story. (2019). Journal of Orthopaedic Research®, 37(6), 1229-35.

[8] Tang SA, Zhang C, Oo WM, Fu K, Risberg MA, Bierma-Zeinstra SM, Neogi T, Atukorala I, Malfait AM, Ding C, Hunter DJ. (2025). Osteoarthritis. Nature Reviews Disease Primers, 11(1), 1-22.

[9] Holden MA, Nicolson PJ, Thomas MJ, Corp N, Hinman RS, Bennell KL. (2023). Osteoarthritis year in review 2022: rehabilitation. Osteoarthritis and cartilage, 31(2), 177-86.

[10] Richard MJ, Driban JB, McAlindon TE. (2023). Pharmaceutical treatment of osteoarthritis. Osteoarthritis and cartilage, 31(4), 458-66.

[11] Lou Z, Bu F. (2025). Recent advances in osteoarthritis research: A review of treatment strategies, mechanistic insights, and acupuncture. Medicine, 104(4), e41335.

[12] Skou ST, Pedersen BK, Abbott JH, Patterson B, Barton C. (2018). Physical activity and exercise therapy benefit more than just symptoms and impairments in people with hip and knee osteoarthritis. Journal of orthopaedic & sports physical therapy, 48(6), 439-47.

[13] Wang W, Niu Y, Jia Q.(2022). Physical therapy as a promising treatment for osteoarthritis: A narrative review. Frontiers in physiology, 13, 1011407.

[14] Kjeken I, Bordvik DH, Osteras N, Haugen IK, Fjeldstad KA, Skaalvik I, Kloppenburg M, Kroon FP, Tveter AT, Smedslund G. (2025). Efficacy and safety of non-pharmacological, pharmacological and surgical treatments for hand osteoarthritis in 2024: a systematic review. RMD open, 11(1), e004963.

[15] Dziedzic KS, Allen KD. (2018). Challenges and controversies of complex interventions in osteoarthritis management: recognizing inappropriate and discordant care. Rheumatology, 57(suppl_4), iv88-98.
[16] Madry H. (2022). Surgical therapy in osteoarthritis. Osteoarthritis and cartilage, 30(8), 1019-34.
[17] Koyonos L, Slenker N, Cohen S. (2012). Complications in brief: osteotomy for lower extremity malalignment. Clinical Orthopaedics and Related Research®, 470, 3630-6.
[18] Lou Z, Bu F. (2025). Recent advances in osteoarthritis research: A review of treatment strategies, mechanistic insights, and acupuncture. Medicine, 104(4), e41335.
[19] Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O. (2025). Recent advances in the management of knee osteoarthritis: a narrative review. Frontiers in Medicine, 12, 1523027.
[20] Liu L, Tang H, Wang Y. (2023). Nanotechnology-boosted biomaterials for osteoarthritis treatment: current status and future perspectives. International journal of nanomedicine,4969-83.
[21] Guo X, Lou J, Wang F, Fan D, Qin Z. (2022). Recent advances in nano-therapeutic strategies for osteoarthritis. Frontiers in Pharmacology, 13, 924387.
[22] Jyothi VG, Katta CB, Singothu S, Preeti K, Bhandari V, Singh SB, Madan J. (2022). Analysis of the therapeutic efficacy of meloxicam-loaded solid lipid nanoparticles topical gel in Wistar rats knee osteoarthritis. Journal of Drug Delivery Science and Technology, 77, 103914.
[23] Sahu T, Ratre YK, Chauhan S, Bhaskar LV, Nair MP, Verma HK. (2021).Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. Journal of Drug Delivery Science and Technology, 63, 102487.
[24] Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M. (2021). Current clinical applications of in vivo gene therapy with AAVs. Molecular Therapy, 29(2), 464-88.
[25] Wang G, Xing D, Liu W, Zhu Y, Liu H, Yan L, Fan K, Liu P, Yu B, Li JJ, Wang B. (2022). Preclinical studies and clinical trials on mesenchymal stem cell therapy for knee osteoarthritis: a systematic review on models and cell doses. International Journal of Rheumatic Diseases, 25(5), 532-62.
[26] Rios JL, Sapède D, Djouad F, Rapp AE, Lang A, Larkin J, Ladel C, Mobasheri A. (2022). Animal models of osteoarthritis Part 1–preclinical small animal models: challenges and opportunities for drug development. Current Protocols, 2(11), e596.
[27] Wang Y, Liu L, Le Z, Tay A. (2022). Analysis of nanomedicine efficacy for osteoarthritis. Advanced NanoBiomed Research, 2(12), 2200085.
[28] Liao S, Jia S, Yue Y, Zeng H, Lin J, Liu P. (2024). Advancements in pH-Responsive nanoparticles for osteoarthritis treatment: Opportunities and challenges. Frontiers in Bioengineering and Biotechnology, 12, 1426794.
[29] Gao J, Xia Z, Mary HB, Joseph J, Luo JN, Joshi N. (2022). Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs.Trends in pharmacological sciences, 43(3), 171-87.
[30] Sagar S, Singh D, Gupta GD. (2021). Recent Development in the Management of Osteoarthritis–Overview of Nanoformulation Approaches. Pharmaceutical Nanotechnology, 9(4), 251-61.
[31] Madav Y, Barve K, Prabhakar B. (2020). Current trends in theranostics for rheumatoid arthritis. European Journal of Pharmaceutical Sciences, 145, 105240.

[32] Suhag D, Kaushik S, Taxak VB. Theranostics: Combining Diagnosis and Therapy. (2024). InHandbook of Biomaterials for Medical Applications, 1, 271-295.
[33] Singh V. (2024). Theranostics: Integrated Diagnostics and Therapy Using Nanomedicine. InNanomedicine, 505-530.
[34] Hamilton AM, Cheung WY, Gómez-Aristizábal A, Sharma A, Nakamura S, Chaboureau A, Bhatt S, Rabani R, Kapoor M, Foster PJ, Viswanathan S. (2019). Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. PLoS One, 14(12), e0214107.
[35] Wu J, Wu C, Cai Z, Gu H, Liu L, Xia C, Lui S, Gong Q, Song B, Ai H. (2023). Ultra-small superparamagnetic iron oxide nanoparticles for intra-articular targeting of cartilage in early osteoarthritis. Regenerative Biomaterials, 10, rbad052.
[36] Spiridon IA, Căruntu ID, Spiridon I, Brăescu R. (2022). Insight into potential biomedical application of mesoporous materials. Pharmaceutics, 14(11), 2382.
[37] Mishra V, Pandey RP, Priyadarshini A, Chang CM, Leal E. (2024). Nanotherapeutics for inflammatory arthritis: design, diagnosis, and treatment.CRC Press.
[38] Chen X, Tian B, Wang Y, Zheng J, Kang X. (2025). Potential and challenges of utilizing exosomes in osteoarthritis therapy. International Journal of Molecular Medicine, 55(3), 43.
[39] Moretti L, Bizzoca D, Geronimo A, Moretti FL, Monaco E, Solarino G, Moretti B. (2022) Towards precision medicine for osteoarthritis: focus on the synovial fluid proteome. International Journal of Molecular Sciences, 23(17), 9731.
[40] Siaton BC, Hogans BH, Hochberg MC. (2021). Precision medicine in osteoarthritis: not yet ready for prime time. Expert Review of Precision Medicine and Drug Development, 6(1), 5-8.
[41] Yang J, Fu X, Liao X, Li Y. (2020). Nrf2 activators as dietary phytochemicals against oxidative stress, inflammation, and mitochondrial dysfunction in autism spectrum disorders: a systematic review. Frontiers in Psychiatry, 11, 561998.
[42] Liang Q, Cheng Z, Qin L. (2024). Advanced nanoparticles in osteoarthritis treatment. Biomaterials Translational, 5(2), 95.
[43] Peiravi M, Sherafat Z, Sani M, Azarpira N. (2025). In vitro and in vivo assessment of 3D-printed PCL/PLA/ZnO nanocomposite scaffolds for osteoarthritis treatment. Composites Communications, 102432.
[44] Bernotiene E, Bagdonas E, Kirdaite G, Bernotas P, Kalvaityte U, Uzieliene I, Thudium CS, Hannula H, Lorite GS, Dvir-Ginzberg M, Guermazi A. (2020). Emerging technologies and platforms for the immunodetection of multiple biochemical markers in osteoarthritis research and therapy. Frontiers in medicine, 7, 572977.
[45] Braaten JA, Banovetz MT, DePhillipo NN, Familiari F, Russo R, Kennedy NI, LaPrade RF. (2022). Biomarkers for osteoarthritis diseases. Life, 12(11), 1799.
[46] Shentu CY, Yan G, Xu DC, Chen Y, Peng LH. (2022). Emerging pharmaceutical therapeutics and delivery technologies for osteoarthritis therapy. Frontiers in Pharmacology, 13, 945876.
[47] Chakraborty S, Gupta NV, Sastri KT, Chand P, Kumar H, Osmani RA, Gowda DV, Jain V. (2022). Current progressions in transdermal drug delivery systems for management of rheumatoid and osteoarthritis: A comprehensive review. Journal of Drug Delivery Science and Technology, 73, 103476.

[48] Liang Q, Cheng Z, Qin L. (2024). Advanced nanoparticles in osteoarthritis treatment. Biomaterials Translational, 5(2), 95.

[49] Yang Y, Zhang H. (2024). Intra-Articular Injection of Nanomaterials for the Treatment of Osteoarthritis: From Lubrication Function Restoration to Cell and Gene Therapy. Advanced Functional Materials, 34(30), 2401547.